Merghoub, Taha

Publications

Sort by

Co-Author Network

selected publications

Determinants of survival in HER2+ metastatic esophagogastric cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Academic Article GET IT
Correction: Multiplexed molecular imaging with surface enhanced resonance Raman scattering nanoprobes reveals immunotherapy response in mice via multichannel image segmentation. Nanoscale horizons. 2023 Article GET IT
MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma. Cancer cell. 2023 Academic Article GET IT
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023 Academic Article GET IT
Times cited: 3
OX40L-expressing recombinant modified vaccinia virus Ankara induces potent antitumor immunity via reprogramming Tregs. The Journal of experimental medicine. 2023 Academic Article GET IT
Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade. Cancer cell. 2023 Academic Article GET IT
Times cited: 1
T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. Cell. 2023 Academic Article GET IT
Times cited: 3
Paving the Way for Cancer Therapy a Nano Step at a Time. The Journal of pharmacology and experimental therapeutics. 2023 Academic Article GET IT
The ectonucleotidase CD39 identifies tumor-reactive CD8⁺ T cells predictive of immune checkpoint blockade efficacy in human lung cancer. Immunity. 2022 Academic Article GET IT
Times cited: 2
Multiplexed molecular imaging with surface enhanced resonance Raman scattering nanoprobes reveals immunotherapy response in mice via multichannel image segmentation. Nanoscale horizons. 2022 Academic Article GET IT
Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant. NPJ vaccines. 2022 Academic Article GET IT
Times cited: 16
A nuclear cAMP microdomain suppresses tumor growth by Hippo pathway inactivation. Cell reports. 2022 Academic Article GET IT
Times cited: 1
Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade. The Journal of clinical investigation. 2022 Academic Article GET IT
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Academic Article GET IT
Times cited: 5
In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response. Nature communications. 2022 Academic Article GET IT
Times cited: 4
Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. Science translational medicine. 2022 Academic Article GET IT
Times cited: 5
Author Correction: Fundamental immune-oncogenicity trade-offs define driver mutation fitness. Nature. 2022 Article GET IT
Times cited: 1
Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma. Cancers. 2022 Academic Article GET IT
Times cited: 359
Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions. The Journal of experimental medicine. 2022 Academic Article GET IT
Times cited: 3
Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature. 2022 Academic Article GET IT
Times cited: 29
Fundamental immune-oncogenicity trade-offs define driver mutation fitness. Nature. 2022 Academic Article GET IT
Times cited: 8
Neutrophil phenotypes and functions in cancer: A consensus statement. The Journal of experimental medicine. 2022 Review GET IT
Times cited: 31
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/- trastuzumab in patients with breast cancer brain metastases. NPJ breast cancer. 2022 Academic Article GET IT
Times cited: 104
Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. Nature communications. 2022 Academic Article GET IT
Times cited: 21
Anatomic position determines oncogenic specificity in melanoma. Nature. 2022 Academic Article GET IT
Times cited: 18
Plasma secretome analyses identify IL-8 and nitrites as predictors of poor prognosis in nasopharyngeal carcinoma patients. Cytokine. 2022 Academic Article GET IT
Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism. Science advances. 2022 Academic Article GET IT
Times cited: 4
In vivo optical imaging-guided targeted sampling for precise diagnosis and molecular pathology. Scientific reports. 2021 Academic Article GET IT
Times cited: 4
Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer. Communications biology. 2021 Academic Article GET IT
Times cited: 5
Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness. JCI insight. 2021 Academic Article GET IT
Times cited: 2
Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer. Frontiers in immunology. 2021 Editorial Article GET IT
Times cited: 4
Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature. 2021 Article GET IT
Times cited: 1
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nature reviews. Clinical oncology. 2021 Review GET IT
Times cited: 173
Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia. Journal for immunotherapy of cancer. 2021 Academic Article GET IT
Times cited: 5
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. Science translational medicine. 2021 Academic Article GET IT
Times cited: 32
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature. 2021 Academic Article GET IT
Times cited: 125
Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 18
Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell. 2021 Academic Article GET IT
Times cited: 69
Tim-4⁺ cavity-resident macrophages impair anti-tumor CD8⁺ T cell immunity. Cancer cell. 2021 Academic Article GET IT
Times cited: 61
Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8⁺ T cells in tumors. Immunity. 2021 Academic Article GET IT
Times cited: 152
CTLA-4 blockade drives loss of T_reg stability in glycolysis-low tumours. Nature. 2021 Academic Article GET IT
Times cited: 130
Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 31
Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma. Cell reports. 2021 Academic Article GET IT
Times cited: 14
Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. Cancer discovery. 2020 Academic Article GET IT
Times cited: 77
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction. Cell. 2020 Academic Article GET IT
Times cited: 177
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. Cell. 2020 Academic Article GET IT
Times cited: 160
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. Journal for immunotherapy of cancer. 2020 Academic Article GET IT
Times cited: 77
Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nature communications. 2020 Academic Article GET IT
Times cited: 131
Innate immune checkpoints for cancer immunotherapy: expanding the scope of non T cell targets. Annals of translational medicine. 2020 Editorial Article GET IT
Times cited: 152
Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. Nature communications. 2020 Academic Article GET IT
Times cited: 43
Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism. Archives of biochemistry and biophysics. 2020 Academic Article GET IT
Times cited: 25
Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer. Cancer research. 2020 Comment GET IT
Times cited: 13
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial. Journal for immunotherapy of cancer. 2020 Academic Article GET IT
Times cited: 20
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. Journal for immunotherapy of cancer. 2020 Review GET IT
Times cited: 459
iNOS Regulates the Therapeutic Response of Pancreatic Cancer Cells to Radiotherapy. Cancer research. 2020 Academic Article GET IT
Times cited: 23
ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature. 2020 Academic Article GET IT
Times cited: 188
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nature immunology. 2020 Academic Article GET IT
Times cited: 242
Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 57
Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Comment GET IT
Times cited: 69
Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1⁺CD38^hi cells and anti-PD-1 resistance. Nature immunology. 2019 Article GET IT
Times cited: 4
In vitro assays for effector T cell functions and activity of immunomodulatory antibodies. Methods in enzymology. 2019 Academic Article GET IT
Times cited: 3
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1⁺CD38^hi cells and anti-PD-1 resistance. Nature immunology. 2019 Academic Article GET IT
Times cited: 169
In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors. The Journal of clinical investigation. 2019 Academic Article GET IT
Times cited: 28
One checkpoint may hide another: inhibiting the TGFβ signaling pathway enhances immune checkpoint blockade. Hepatobiliary surgery and nutrition. 2019 Editorial Article GET IT
Times cited: 378
Massively parallel sequencing analysis of benign melanocytic naevi. Histopathology. 2019 Academic Article GET IT
Times cited: 10
Rational design of anti-GITR-based combination immunotherapy. Nature medicine. 2019 Academic Article GET IT
Times cited: 137
Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. Cell reports. 2019 Academic Article GET IT
Times cited: 36
Targeted APC Activation in Cancer Immunotherapy to Enhance the Abscopal Effect. Frontiers in immunology. 2019 Review GET IT
Times cited: 33
Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer. Oncoimmunology. 2019 Academic Article GET IT
Times cited: 11
Correction to: Strategies for Predicting Response to Checkpoint Inhibitors. Current hematologic malignancy reports. 2019 Article GET IT
An Antitumor Immune Response Is Evoked by Partial-Volume Single-Dose Radiation in 2 Murine Models. International journal of radiation oncology, biology, physics. 2018 Academic Article GET IT
Times cited: 46
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer cell. 2018 Academic Article GET IT
Times cited: 44
Non-conventional Inhibitory CD4⁺Foxp3^-PD-1^hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. Cancer cell. 2018 Academic Article GET IT
Times cited: 11
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. The Journal of clinical investigation. 2018 Academic Article GET IT
Times cited: 18
Strategies for Predicting Response to Checkpoint Inhibitors. Current hematologic malignancy reports. 2018 Review GET IT
Times cited: 21
Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade. 2018 GET IT
Times cited: 99
Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus. Oncotarget. 2018 Academic Article GET IT
Times cited: 21
Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins. Cancer discovery. 2018 Academic Article GET IT
Times cited: 189
Non-conventional Inhibitory CD4⁺Foxp3^-PD-1^hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. Cancer cell. 2018 Academic Article GET IT
Times cited: 96
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. The New England journal of medicine. 2018 Academic Article GET IT
Times cited: 1125
Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell. 2018 Academic Article GET IT
Times cited: 88
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer cell. 2018 Academic Article GET IT
Times cited: 648
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer cell. 2018 Review GET IT
Times cited: 326
Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. PloS one. 2018 Academic Article GET IT
Times cited: 16
The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells. Molecular cell. 2018 Academic Article GET IT
Times cited: 12
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. The Journal of clinical investigation. 2018 Academic Article GET IT
Times cited: 87
Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy. Molecular therapy : the journal of the American Society of Gene Therapy. 2018 Academic Article GET IT
Times cited: 88
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 882
Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. Cancer immunology research. 2018 Academic Article GET IT
Times cited: 95
Antiangiogenic therapy and immune checkpoint blockade go hand in hand. Annals of translational medicine. 2017 Editorial Article GET IT
Times cited: 364
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature. 2017 Academic Article GET IT
Times cited: 395
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017 Academic Article GET IT
Times cited: 679
Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 65
Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation. Oncotarget. 2017 Academic Article GET IT
Times cited: 7
Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment. Science signaling. 2017 Academic Article GET IT
Times cited: 84
Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. 2017 GET IT
Times cited: 317
PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma. JCO precision oncology. 2017 Academic Article GET IT
Times cited: 28
Curbing Tregs' (Lack of) Enthusiasm. Cell. 2017 Comment GET IT
Times cited: 4
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. PLoS medicine. 2017 Academic Article GET IT
Times cited: 209
mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition. Oncotarget. 2017 Academic Article GET IT
Times cited: 16
Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells. Science immunology. 2017 Academic Article GET IT
Times cited: 79
Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature. 2017 Academic Article GET IT
Times cited: 496
HMG-CoA synthase 1 is a synthetic lethal partner of BRAF^V600E in human cancers. The Journal of biological chemistry. 2017 Academic Article GET IT
Times cited: 25
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 2017 Academic Article GET IT
Times cited: 54
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 419
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nature communications. 2017 Academic Article GET IT
Times cited: 93
Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma. The Journal of investigative dermatology. 2017 Academic Article GET IT
Times cited: 18
Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. Cell metabolism. 2017 Academic Article GET IT
Times cited: 93
An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity. Molecular therapy oncolytics. 2017 Academic Article GET IT
Times cited: 59
Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. Oncotarget. 2016 Academic Article GET IT
Times cited: 43
Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade. Cancer immunology research. 2016 Academic Article GET IT
Times cited: 90
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature. 2016 Academic Article GET IT
Times cited: 557
Interfering with Helios-induced regulatory T cell stability as a strategy for cancer immunotherapy. Translational cancer research. 2016 Academic Article GET IT
Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells. Cancer immunology research. 2016 Academic Article GET IT
Times cited: 104
The metabolic/pH sensor soluble adenylyl cyclase is a tumor suppressor protein. Oncotarget. 2016 Academic Article GET IT
Times cited: 15
In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide. Science immunology. 2016 Academic Article GET IT
Times cited: 101
Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy. Oncoimmunology. 2016 Academic Article GET IT
Times cited: 4274
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science (New York, N.Y.). 2016 Academic Article GET IT
Times cited: 2058
Protein Expression Analysis of Melanocyte Differentiation Antigen TRP-2. The American Journal of dermatopathology. 2016 Academic Article GET IT
Times cited: 4
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 2016 Article GET IT
Times cited: 49
Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. EBioMedicine. 2016 Academic Article GET IT
Times cited: 106
Clonal Abundance of Tumor-Specific CD4(+) T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion. Immunity. 2016 Academic Article GET IT
Times cited: 28
IL-6/NOS2 inflammatory signals regulate MMP-9 and MMP-2 activity and disease outcome in nasopharyngeal carcinoma patients. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2015 Academic Article GET IT
Times cited: 18
Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature. 2015 Academic Article GET IT
Times cited: 162
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell reports. 2015 Academic Article GET IT
Times cited: 324
Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations. Immunotherapy. 2015 Review GET IT
Times cited: 3
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 2015 Academic Article GET IT
Times cited: 1043
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. Molecular cell. 2015 Academic Article GET IT
Times cited: 107
The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy. Advances in cancer research. 2015 Review GET IT
Times cited: 40
A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. The oncologist. 2015 Academic Article GET IT
Times cited: 54
Genetics and immunology: reinvigorated. Oncoimmunology. 2015 Academic Article GET IT
Times cited: 3186
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (New York, N.Y.). 2015 Academic Article GET IT
Times cited: 5785
Genetic basis for clinical response to CTLA-4 blockade in melanoma. The New England journal of medicine. 2014 Academic Article GET IT
Times cited: 3140
Immunotherapy and the belly of the beast. The Journal of experimental medicine. 2014 Comment GET IT
Times cited: 1
Modified vaccinia virus Ankara triggers type I IFN production in murine conventional dendritic cells via a cGAS/STING-mediated cytosolic DNA-sensing pathway. PLoS pathogens. 2014 Academic Article GET IT
Times cited: 110
T cells translate individual, quantal activation into collective, analog cytokine responses via time-integrated feedbacks. eLife. 2014 Academic Article GET IT
Times cited: 49
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Science translational medicine. 2014 Academic Article GET IT
Times cited: 535
Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. 2014 GET IT
Times cited: 67
Broad-spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation. Cell. 2014 Academic Article GET IT
Times cited: 128
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer research. 2014 Academic Article GET IT
Times cited: 228
Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates. Cancer immunology research. 2014 Academic Article GET IT
Times cited: 30
Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice. Blood. 2014 Academic Article GET IT
Times cited: 22
Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. Cancer immunology research. 2014 Academic Article GET IT
Times cited: 87
The importance of animal models in tumor immunity and immunotherapy. Current opinion in genetics & development. 2013 Review GET IT
Times cited: 56
Enhanced responses to tumor immunization following total body irradiation are time-dependent. PloS one. 2013 Academic Article GET IT
Times cited: 11
GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. Cancer immunology research. 2013 Academic Article GET IT
Times cited: 119
Myeloid-derived suppressor sells and the efficacy of CD8⁺ T-cell immunotherapy. Oncoimmunology. 2013 Academic Article GET IT
Times cited: 1584
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer cell. 2012 Academic Article GET IT
Times cited: 397
Progression of RAS-mutant leukemia during RAF inhibitor treatment. 2012 GET IT
Times cited: 197
Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. The Journal of experimental medicine. 2012 Academic Article GET IT
Times cited: 110
EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 33
Innate immune response of human plasmacytoid dendritic cells to poxvirus infection is subverted by vaccinia E3 via its Z-DNA/RNA binding domain. PloS one. 2012 Academic Article GET IT
Times cited: 26
Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer research. 2011 Academic Article GET IT
Times cited: 270
Myxoma virus induces type I interferon production in murine plasmacytoid dendritic cells via a TLR9/MyD88-, IRF5/IRF7-, and IFNAR-dependent pathway. Journal of virology. 2011 Academic Article GET IT
Times cited: 31
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene. 2011 Academic Article GET IT
Times cited: 159
Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope. PloS one. 2011 Academic Article GET IT
Times cited: 12
Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice. Vaccine. 2011 Academic Article GET IT
Times cited: 11
Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. PloS one. 2010 Academic Article GET IT
Times cited: 58
Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PloS one. 2010 Academic Article GET IT
Times cited: 211
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. The Journal of experimental medicine. 2010 Academic Article GET IT
Times cited: 610
Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood. 2010 Academic Article GET IT
Times cited: 96
The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease. The Journal of clinical investigation. 2009 Academic Article GET IT
Times cited: 61
LRF is an essential downstream target of GATA1 in erythroid development and regulates BIM-dependent apoptosis. Developmental cell. 2009 Academic Article GET IT
Times cited: 87
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. The Journal of experimental medicine. 2009 Academic Article GET IT
Times cited: 177
Immune rejection of mouse tumors expressing mutated self. Cancer research. 2009 Academic Article GET IT
Times cited: 14
Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. The Journal of experimental medicine. 2009 Academic Article GET IT
Times cited: 87
Development of effective vaccines for old mice in a tumor model. Vaccine. 2008 Academic Article GET IT
Times cited: 6
Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. Cancer research. 2008 Academic Article GET IT
Times cited: 27
Vaccinia virus subverts a mitochondrial antiviral signaling protein-dependent innate immune response in keratinocytes through its double-stranded RNA binding protein, E3. Journal of virology. 2008 Academic Article GET IT
Times cited: 40
Mechanisms of immunization against cancer using chimeric antigens. Molecular therapy : the journal of the American Society of Gene Therapy. 2008 Academic Article GET IT
Times cited: 13
Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF. Science (New York, N.Y.). 2007 Academic Article GET IT
Times cited: 177
Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer research. 2006 Academic Article GET IT
Times cited: 177
Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. The Journal of clinical investigation. 2006 Academic Article GET IT
Times cited: 78
Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature. 2005 Academic Article GET IT
Times cited: 292
Disruption of PLZP in mice leads to increased T-lymphocyte proliferation, cytokine production, and altered hematopoietic stem cell homeostasis. Molecular and cellular biology. 2004 Academic Article GET IT
Times cited: 44
Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. Blood. 2003 Academic Article GET IT
Times cited: 61
Atypical t(15;17)(q13;q12) in a patient with all-trans retinoic acid refractory secondary acute promyelocytic leukemia: a case report and review of the literature. Cancer genetics and cytogenetics. 2002 Review GET IT
Times cited: 4
Plzf mediates transcriptional repression of HoxD gene expression through chromatin remodeling. Developmental cell. 2002 Academic Article GET IT
Times cited: 146
Maternally transmitted severe glucose 6-phosphate dehydrogenase deficiency is an embryonic lethal. The EMBO journal. 2002 Academic Article GET IT
Times cited: 121
Altered myelopoiesis and the development of acute myeloid leukemia in transgenic mice overexpressing cyclin A1. Proceedings of the National Academy of Sciences of the United States of America. 2001 Academic Article GET IT
Times cited: 68
Modeling acute promyelocytic leukemia in the mouse: new insights in the pathogenesis of human leukemias. Blood cells, molecules & diseases. 2001 Review GET IT
Times cited: 11
BCL-6 regulates chemokine gene transcription in macrophages. Nature immunology. 2000 Academic Article GET IT
Times cited: 148
In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications. Oncogene. 1999 Review GET IT
Times cited: 91
New method for quantitative determination of fetal hemoglobin-containing red blood cells by flow cytometry: application to sickle-cell disease. Cytometry. 1998 Academic Article GET IT
Times cited: 24
Dissection of the association status of two polymorphisms in the beta-globin gene cluster with variations in F-cell number in non-anemic individuals. American journal of hematology. 1997 Academic Article GET IT
Times cited: 17
Variation of fetal hemoglobin and F-cell number with the LCR-HS2 polymorphism in nonanemic individuals. Blood. 1996 Letter GET IT
Times cited: 19

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Image-guided Trp-IDO/TDO-Kyn-AHR pathway inhibition, combined with immunotherapy awarded by National Cancer Institute Principal Investigator 2022 - 2026
Nonclinical Research Agreement - BMS awarded by Bristol-Myers Squibb Company Principal Investigator 2023 - 2025
Sponsored Research Agreement - Merghoub Lab awarded by ReAlta Life Sciences, Inc. Principal Investigator 2023 - 2024
Mechanism-Based Approach for Combination Therapies with Immune Modulation for Management of Patients with Urothelial Cancers of the Upper Urinary Tract awarded by United States Department of Defense Principal Investigator 2022 - 2024

Ludwig Collaborative Laboratory awarded by Ludwig Institute for Cancer Research Co-Investigator 2022 - 2027
DNA Vaccines Against Cancer and Infectious Organisms awarded by Breast Cancer Research Foundation, Inc. Co-Investigator 2022 - 2023

Weill Cornell Medicine (WCM) SPORE in Prostate Cancer awarded by National Cancer Institute Key Personnel 2017 - 2023

Group 2 Innate Lymphoid Cell Regulation of Pancreatic Cancer Immunity awarded by National Institute of Diabetes & Digestive & Kidney Diseases Principal Investigator Subaward 2022 - 2027
Bridging predictive models and precision immunotherapies awarded by National Institute of Diabetes & Digestive & Kidney Diseases Principal Investigator Subaward 2022 - 2024

more ...

less ...

Background

education and training

Ph.D., University of Paris VII, Denis Diderot (France) 1997
M.Sc., University of Paris VII, Denis Diderot (France) 1992
B.A., University of Paris VII, Denis Diderot (France) 1991
B.A., University of Algeria (Algeria) 1990

Contact

full name

Taha Merghoub

primary email

tmerghoub@med.cornell.edu

VIVO Weill Cornell Medical College

Taha Merghoub Professor of Research in Pharmacology

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email